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Tuberous sclerosis complex (TSC) is an autosomal dominantly inherited neurocutaneous disorder caused by inactivating mutations
in TSC1 or TSC2, key regulators of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. In the CNS, TSC is
characterized by cortical tubers, subependymal nodules and subependymal giant cell astrocytomas (SEGAs). SEGAs may lead to
impaired circulation of CSF resulting in hydrocephalus and raised intracranial pressure in patients with TSC. Currently, surgical
resection and mTORC1 inhibitors are the recommended treatment options for patients with SEGA. In the present study, high-
throughput RNA-sequencing (SEGAs n = 19, periventricular control n = 8) was used in combination with computational
approaches to unravel the complexity of SEGA development. We identified 9400 mRNAs and 94 microRNAs differentially
expressed in SEGAs compared to control tissue. The SEGA transcriptome profile was enriched for the mitogen-activated protein
kinase (MAPK) pathway, a major regulator of cell proliferation and survival. Analysis at the protein level confirmed that extra-
cellular signal-regulated kinase (ERK) is activated in SEGAs. Subsequently, the inhibition of ERK independently of mTORC1
blockade decreased efficiently the proliferation of primary patient-derived SEGA cultures. Furthermore, we found that LAMTOR1,
LAMTOR2, LAMTOR3, LAMTOR4 and LAMTOR5 were overexpressed at both gene and protein levels in SEGA compared to
control tissue. Taken together LAMTOR1–5 can form a complex, known as the ‘Ragulator’ complex, which is known to activate
both mTORC1 and MAPK/ERK pathways. Overall, this study shows that the MAPK/ERK pathway could be used as a target for
treatment independent of, or in combination with mTORC1 inhibitors for TSC patients. Moreover, our study provides initial
evidence of a possible link between the constitutive activated mTORC1 pathway and a secondary driver pathway of tumour
growth.
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Introduction
Tuberous sclerosis complex (TSC) is a multisystem genetic
disorder affecting approximately 1 million individuals
worldwide. It is caused by mutations in either TSC1 or
TSC2 and is characterized by the development of benign
tumours in multiple organs, including the brain (European
Chromosome 16 Tuberous Sclerosis Consortium, 1993;
van Slegtenhorst et al., 1997; DiMario, 2004). In the
CNS, TSC is associated with subcortical/cortical tubers,
subependymal nodules and subependymal giant cell astro-
cytomas (SEGAs) (Mizuguchi and Takashima, 2001;
Aronica et al., 2012; Aronica and Crino, 2014).
SEGAs are benign slow growing tumours classified as
WHO grade I representing 1–2% of all paediatric brain
tumours and occur almost exclusively in patients with
TSC (Jozwiak et al., 2015; Louis et al., 2016). The preva-
lence of SEGAs in patients with TSC ranges from 5% to
25% and they usually arise during the first two decades of
life (Cuccia et al., 2003; Goh et al., 2004; Adriaensen et al.,
2009; Kothare et al., 2014; Kingswood et al., 2017).
SEGAs arise around the ventricle zone, mostly at the
height of the foramen of Monro and are thought to develop
from subependymal nodules (Morimoto and Mogami,
1986; Fujiwara et al., 1989; Nabbout et al., 1999).
Despite their slow growing nature, extended growth of
the tumour can cause obstruction of the cerebral fluid
tract leading to (acute) hydrocephalus and in rare cases
even sudden death (de Ribaupierre et al., 2007; Kotulska
et al., 2014).
Hamartin (TSC1), tuberin (TSC2) and TBC1 domain
family member 7 (TBC1D7) can form a complex contain-
ing a GTPase-activating protein (GAP) for the small
GTPase Ras homologue enriched in brain 1 (RHEB1), a
direct positive regulator of the mechanistic target of rapa-
mycin complex 1 (mTORC1) located on the late endosome/
lysosome surface (Inoki et al., 2003; Sancak et al., 2008;
Dibble et al., 2012). Loss of function mutations in TSC1 or
TSC2 result in constitutive activation of the mTORC1
pathway (CHan et al., 2004). In TSC, germline mutations
in TSC1 or TSC2 can be familial inherited in a autosomal
dominant fashion, but more often are sporadic in nature.
Furthermore, loss of heterozygosity of TSC1 or TSC2 has
been reported in 80% of SEGAs (CHan et al., 2004;
Bongaarts et al., 2017; Martin et al., 2017). However,
‘second-hit’ mutations in TSC1 and TSC2 are not always
observed in brain lesions including SEGA, suggesting that
additional genetic events are involved in the growth and
progression of SEGAs. Several studies have reported an
activation of the mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated kinase (ERK) path-
way in SEGA (Han et al., 2004; Ma et al., 2005, 2007)
and it has been shown that inhibiting ERK can effect the
proliferation of SEGA cells (Tyburczy et al., 2010), indicat-
ing that the MAPK/ERK pathway could play an important
role in SEGA development. Furthermore, it has been shown
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that both the mTORC1 and MAPK/ERK pathway can be
activated by the lysosomal Ragulator complex consisting of
late endosomal/lysosomal adaptor, MAPK and mTOR ac-
tivator 1–5 (LAMTOR1/p18, LAMTOR2/p14, LAMTO
R3/MP1, LAMTOR4/C7orf59 and LAMTOR5/HBXIP)
(Teis et al., 2002; Bar-Peled et al., 2012; Nada et al.,
2014; de Araujo et al., 2017). Therefore, the role of the
Ragulator complex in the development of SEGAs warrants
further investigation.
Current treatment options for growing SEGAs include
surgical resection or use of mTORC1 inhibitors, such as
everolimus and rapamycin (Franz et al., 2006, 2013,
2014, 2015; Krueger et al., 2010; Kotulska et al., 2013;
Krueger et al., 2013). Although mTORC1 inhibitors have
been shown to be effective in patients with TSC, the re-
sponse to mTORC1 inhibitors can be variable and cessa-
tion of treatment may result in tumour regrowth (Franz
et al., 2006, 2014; Bissler et al., 2008; Krueger et al.,
2010, 2016; McCormack et al., 2011; Martins et al.,
2013).
Previous gene expression studies on SEGA focus on the
expression of protein-coding genes using either a micro-
array (Tyburczy et al., 2010) or RNA sequencing (RNA-
seq; Martin et al., 2017). In the present study, we aimed to
map both the protein-coding and non-coding RNA, includ-
ing small RNAs, of SEGA compared to periventricular con-
trol tissue in order to identify signaling pathways




Twenty-one SEGA specimens were obtained from the follow-
ing sites: Amsterdam UMC (location AMC), University
Medical Center Utrecht, University Medical Center
Groningen, Medical University of Vienna, Children’s
Memorial Health Institute in Warsaw and Meyer Children’s
Hospital in Florence. Nineteen of the 21 SEGA samples
included in this study were obtained from patients who met
the clinical diagnostic criteria for TSC. From the 21 SEGA
samples 19 were selected and used for RNA-sequencing
(RNA-Seq) (Table 1). When DNA material permitted, TSC1/
TSC2 mutation analysis was performed as part of routine clin-
ical care on blood or tumour sample DNA or was determined
using massively parallel sequencing (including analysis of loss
of heterozygosity) as described previously (Northrup et al.,
2013; Bongaarts et al., 2017) (Table 1). Histological diagnosis
was confirmed following the current WHO classification
guidelines by two independent neuropathologists (Louis
et al., 2016). The following clinical data were extracted from
medical records: TSC1/TSC2 mutation status, gender, localiza-
tion of the resected area, age at seizure onset, duration of
active epilepsy, drug management at time of surgery (including
treatment with mTORC1 inhibitors), size of the tumour,
tumour recurrence/regrowth and presence of other TSC-related
malformations. No peri-tumoural tissue was available,
therefore periventricular brain tissue was obtained (as well as
one sample of cortex tissue) from autopsy controls without a
history of TSC, epilepsy or brain tumours. Thirteen controls
were obtained of which eight were selected for RNA-Seq and
five were used for additional immunohistochemistry.
Additionally, four cortical tubers, one angiomyolipoma and
one sample of normal renal tissue were obtained from TSC
patients who met the clinical diagnostic criteria for TSC
(Supplementary Table 1). Specimens were obtained and used
in accordance with the Declaration of Helsinki and this study
was approved by the Medical Ethics Committees of each
institution.
RNA isolation and RNA sequencing
For RNA isolation frozen tissue or cultured cells were homo-
genized with Qiazol Lysis Reagent (Qiagen). The total RNA
including the microRNA (miRNA) fraction was isolated using
the miRNeasy Mini kit (Qiagen) according to manufacturer’s
instructions. The concentration of RNA was determined using
a NanoDropTM 2000 spectrophotometer (Thermo Fisher
Scientific) for cell cultures or Qubit 2.0 Fluorometer (Life
Technologies) for frozen tissue. For RNA-Seq the RNA integ-
rity was assessed using a Bioanalyser 2100 (Agilent). Library
preparation and sequencing were completed at GenomeScan.
The Illumina RNA-Seq and TruSeq Small RNA-Seq sample
preparation kits were used to prepare sequencing libraries of
mRNA and small RNA in accordance to manufacturers guide-
lines. Clustering and DNA sequencing was performed using
the Illumina cBot and HiSeq 2500 according to manufacturer’s
protocols. Each library was subjected to paired-end sequen-
cing, producing reads of 125 nucleotides in length with a
read-depth of 36 million reads for RNA-Seq and 12 million
reads for small RNA-Seq.
Bioinformatics analysis of
RNA-Sequencing data
Read quality was assessed using FastQC v0.11.5 (Babraham
Institute, Babraham, Cambridgeshire, UK). Trimmomatic
v0.36 was used to trim and filter reads of low quality
(Bolger et al., 2014). Low quality leading and trailing bases
were removed from each read, the quality of the body of the
reads was assessed with a sliding window trimming using a
window of 4 and a Phred score threshold of 20 and 15 nu-
cleotides, in our RNA and small RNA datasets, respectively.
Reads that dropped below 80 nucleotides in our RNA dataset
and 17 nucleotides, in our small RNA datasets, as well as
reads with no partner forward or reverse read were excluded
from further analysis.
For small RNA-Seq paired-end reads were aligned to the
reference genome, GRCh38 using TopHat2 v2.0.13 (Kim
et al., 2013). No mismatches were allowed between the
trimmed reads and the reference genome and small RNA
reads were allowed to align a maximum of 10 times (Kim
et al., 2013). Next, transcripts for each sample were assembled
de novo using Cufflinks v2.2.1 using the default settings,
except that the expression of each transcript was not corrected
for length (Trapnell et al., 2012). The transcript assembly for
each sample, along with a custom reference annotation con-
sisting of short RNA species extracted from Gencode v25
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(Harrow et al., 2012) and miRNAs from miRBase21
(Griffiths-Jones et al., 2008) were passed onto Cuffmerge
v2.2.1 (Trapnell et al., 2012). Cuffmerge compared the de
novo transcript assembly of each sample with reference anno-
tation of known miRNAs and short non-coding RNAs. This
allowed each assembled transcript to be classified as a known
short non-coding species, miRNAs or as a novel short non-
coding RNA. Next, all assembled novel transcripts 4100 nu-
cleotides were removed from the analysis. Subsequently, the
chromosomal location of the novel short non-coding RNAs
were compared to the location of the known genes, based on
GENCODE v25, and were classified as unannotated intergenic
or unannotated gene derived. These elements were then all
merged together to create a final reference annotation that
consisted of miRNAs, short RNA species, unannotated inter-
genic short RNA or unannotated gene derived short RNAs.
This reference annotation file along with the original small
RNA read alignment files were passed to featureCounts from
the Subread package and the number of reads that aligned to
each transcripts were counted (Liao et al., 2014).
For the RNA dataset paired-end reads were aligned to the
reference genome, GRCh38 using TopHat2 v2.0.13 and the
default settings (Kim et al., 2013). The number of reads that
aligned to each gene, based on GENCODE v25, were deter-
mined using the featureCounts program from the Subread
package (Liao et al., 2014). The RNA and small RNA count
matrices were passed on to the R package DESeq2 and were
normalized using the median of ratios method ((Love et al.,
2014). Genes and small RNAs with a Benjamini-Hochberg
adjusted P-value 5 0.05 were considered differentially ex-
pressed. The biotypes of all the differentially expressed genes
(DEGs) were assessed using BioMart (Smedley et al., 2009).
Based on the biotype assigned by BioMart the genes were fur-
ther grouped into five categories: (i) protein-coding: all genes
with protein-coding ability; (ii) pseudogenes: all genes classified
as one of the following; polymorphic pseudogene, processed
pseudogene, unprocessed pseudogene, or transcribed processed
pseudogene; (iii) long non-coding RNAs: all genes classed as
long non-coding RNAs; (iv) undefined: genes which could not
be classified; and (v) other: genes that had one or more bio-
types or did not fit into any of the aforementioned categories.
Target prediction tools
RNA-Seq and small RNA-Seq data were integrated using the R
package ‘piano’ (Varemo et al., 2013) and custom scripts writ-
ten in R. The ‘piano’ package is an open-source tool for per-
forming gene set enrichment analysis (GSEA) using a selection
of available methods. The whole RNA transcriptome profile
and the Reactome (Croft et al., 2011; Fabregat et al., 2018)
gene to pathway dataset were passed to ‘piano’. The Wilcoxon
rank-sum test method was used to identify enriched gene sets
amongst the dataset. Significance values were calculated
through random gene sampling. Briefly, a random set of
genes equal in size to the gene set being tested was selected
and the gene set statistic was recalculated (Varemo et al.,
2013). This was repeated 10 000 times to give a discrete null
distribution. The gene set P-value was based on the fraction of
random gene set statistics that are equal to or more extreme
than the original gene set statistic. All P-values were corrected
using the Benjamini-Hochberg method. Gene sets with an ad-
justed P-value 5 0.05 for non-directional, mixed-directional
up and mixed-directional down were considered enriched.
Next, gene sets that were enriched for DEGs were identified
using Fisher’s exact test. Gene sets with a Benjamini-Hochberg
adjusted P-value 5 0.05 were considered enriched for DEGs.
Results were visualized using Cytoscape (Shannon et al.,
2003). The web-accessible program DAVID (https://david.
ncifcrf.gov/) was used to determine enriched pathways
(Benjamini-Hochberg adjusted P-value 5 0.05) from the over-
lapping DEGs between our study and the study by Martin
et al. (2017) (Huang da et al., 2009a, b). Protein-protein inter-
actions were determined for selected DEGs using the
STRINGapp in Cytoscape, allowing 50 protein interactions,
including scores with a confidence of 40.7 for: databases,
text mining, experiments, co-expression, co-occurrence and
neighbourhood (Doncheva et al., 2019).
Gene sets that were potentially modulated by miRNAs were
then identified. First, the list of validated miRNA targets for
each of the differentially expressed miRNAs was retrieved
from miRWalk2 (Dweep et al., 2011, 2014). Each gene set
that was enriched for DEGs was then assessed for over-
representation of miRNA targets using Fisher’s exact test.
Gene sets with a Benjamini-Hochberg adjusted P-value 5
0.05 were considered enriched for validated miRNA targets.
The expression levels of selected differentially expressed
miRNAs and DEGs were correlated to identify potentially im-
portant miRNA-mRNA interaction partners. Correlations
were calculated using Spearman’s rank correlation, statistically
significant correlations (adjusted P-value 5 0.05) of 40.5 and
5–0.5 were deemed as potentially interesting interactions
partners.
Real-time quantitative PCR analysis
Messenger RNA expression levels were evaluated as described
previously (Bongaarts et al., 2018). Briefly, 250 ng of total
RNA was reverse-transcribed into cDNA using oligo-dT pri-
mers. Real-time quantitative PCRs (RT-qPCRs) were run ac-
cording to the manufacturer’s instructions, on a Roche
LightCycler 480 thermocycler (Roche Applied Science)
using LightCycler 480 SYBR Green I Master (Roche
Applied Science) and primers listed in Supplementary Table
2. The expression of miRNAs was analysed using
TaqManTM miRNA assays (Applied Biosystems). cDNA was
generated using the TaqManTM miRNA reverse transcription
kit (Applied Biosystems) according to the manufacturer’s in-
structions, and the PCRs were run on a Roche LightCycler
480 thermocycler (Roche Applied Science).
Quantification was performed using the LinRegPCR soft-
ware in which linear regression on the Log (fluorescence) per
cycle number data is applied to determine the amplification
efficiency per sample (Ramakers et al., 2003; Ruijter et al.,
2009). The starting concentration (predicted by the
LinRegPCR prediction model) of each specific mRNA product
was divided by the starting concentration of the reference gene
elongation factor 1-alpha 1 (EEF1A1) and this ratio was
compared between groups. The starting concentrations
of miRNA-20a-5p, miRNA-34a-5p, miRNA-130b-3p and
miRNA-181a-5p were divided by the geometric mean of the
starting concentrations of reference genes [the U6B small nu-
clear RNA gene (RNU6-6P) and RNU44 (SNORD44)] and
this ratio was compared between groups.
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Immunohistochemistry
Tissue from control brain and SEGA was fixed in 10% buf-
fered formalin and embedded in paraffin. Paraffin-embedded
tissue was sectioned at 6 mm, mounted on precoated slides
(StarFrost, Waldemar Knittel) and stained with haematoxylin
and eosin for the morphological evaluation. Sections of the
most representative paraffin-embedded specimen of each case
were used for double labelling.
Sections were deparaffinated in xylene, rinsed in ethanol
(100%, 95% and 70%) and incubated for 20 min in 0.3%
hydrogen peroxide (H2O2) in methanol to block endogenous
peroxidase activity. Antigen retrieval was performed by incu-
bating the sections in 0.1 M citrate buffer pH 6.0 at 120C for
10 min using a pressure cooker. Sections were washed with
phosphate-buffered saline (PBS, pH 7.4) and incubated with
10% normal goat serum (NGS) for 30 min at room tempera-
ture. Primary antibodies (1:200 rabbit monoclonal IgG anti-
LAMTOR1, 8975, Cell Signaling) in Normal Antibody
Diluent (ImmunoLogic) were incubated overnight at 4C.
After washing with PBS, sections were incubated with
BrightVision poly-alkaline phosphatase (AP)-anti-rabbit
(ImmunoLogic) for 30 min at room temperature. AP activity
was visualized with the AP substrate kit III Vector Blue (SK-
5300, Vector laboratories Inc.). To remove the first primary
antibody, sections were incubated at 120C in citrate buffer
(10 mM NaCi, pH 6.0) for 10 min. Incubation with the
second primary antibody (1:400 rabbit monoclonal IgG anti-
phospho-ERK1/ERK2, 4370S, Cell Signaling; 1:200 rabbit
monoclonal IgG anti-pS6, 4857, Cell Signaling) was performed
overnight at 4C. Sections were stained with a polymer-based
peroxidase immunohistochemistry detection kit (BrightVision
plus kit, ImmunoLogic) according to the manufacturer’s in-
structions. Staining was performed using 3-amino-9-ethyl car-
bazole (AEC, Sigma-Aldrich) in 0.05 M saline buffer pH 4.9
with 0.01% H2O2.
Astrocyte and SEGA cell cultures
Primary foetal astrocyte-enriched cell cultures were obtained
from human foetal brain tissue (14–19 gestational weeks) ob-
tained from medically induced abortions. All material was col-
lected from donors from whom written informed consent for
the use of the material for research purposes had been ob-
tained by the Bloemenhove clinic. Tissue was obtained in ac-
cordance with the Declaration of Helsinki and the Amsterdam
UMC (location AMC) Research Code provided by the Medical
Ethics Committee of the AMC. The SEGA cell culture was
derived from surgical brain specimen obtained from one TSC
patient (age at surgery: 25; gender: female; mutation: TSC1)
undergoing surgery at Medical University of Vienna (Austria).
Primary foetal astrocyte-enriched cell cultures and the primary
SEGA culture were prepared as previously described (van
Scheppingen et al., 2016, 2018). Briefly, visible blood vessels
were removed, after which the tissue was mechanically minced
into smaller fragments and enzymatically digested at 37C for
30 min with 2.5% trypsin (Sigma-Aldrich). Tissue was washed
with incubation medium consisting of Dulbecco’s modified
Eagle medium (DMEM)/HAM F10 (1:1) medium (Gibco,
Life Technologies), supplemented with 50 units/ml penicillin,
50 mg/ml streptomycin, and 10% foetal calf serum (Gibco, Life
Technologies) and passed through a 70-mm mesh filter. The
cell suspension was incubated at 37C, 5% CO2 for 48 h to
allow time for glial cells to adhere to the culture flask and was
then washed with PBS to remove excess of myelin and cell
debris. Cultures were subsequently refreshed twice a week
with incubation medium.
Transfection and treatment of cell
cultures
SEGA cells were plated and stimulated with a final concentra-
tion of 5 mM U0126 (Sigma-Aldrich), 0.1 mM rapamycin (LC
Laboratories) in dimethyl sulphoxide (DMSO) (0.05% final
DMSO concentration) or vehicle (0.05% DMSO) for 24 h.
Primary astrocyte cells were transfected with mimic pre-
miRNA for miRNA-20a-5p (mirVana miRNA mimics,
Applied Biosystems) using Lipofectamine 2000 transfection
reagent (Life Technologies) in a final concentration of 50
nM for 24 h. Cells treated with Lipofectamine without
mimic were used as a control.
Western blot analysis
Western blot analysis was performed as described previously
(Korotkov et al., 2018). Equal amounts of proteins (10 mg/lane
for cell culture samples or 20 mg/lane for tissue samples) were
separated using sodium dodecylsulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE). Blots were blocked for 1 h in either
1% bovine serum albumin (BSA) or 5% non-fat dried milk in
Tris-buffered saline-Tween (TBS-T: 20 mM Tris, 150 mM
NaCl, 0.1% Tween 20, pH 7.5). Blots were incubated over-
night at 4C with primary antibodies for LAMTOR1 (1:200
mouse monoclonal, clone SL-1 IIIC4, EMD Millipore), ERK1/
ERK2 (1:1500 rabbit monoclonal IgG, 9102S, Cell Signaling),
phospho-ERK1/ERK2 (1:1500 rabbit monoclonal IgG, 4370S,
Cell Signaling), S6 (1:1000 rabbit monoclonal IgG, 2217, Cell
Signaling), pS6 (1:1000 rabbit monoclonal IgG, 4857, Cell
Signaling) or b-tubulin (1:30 000 monoclonal mouse, Sigma-
Aldrich). After washing with TBS-T, blots were incubated for
1 h with secondary antibodies: goat anti-mouse IgG1 or goat
anti-rabbit IgG1 coupled to horseradish peroxidase (both
1:2500; Dako). Immunoreactivity was visualized using ECL
western blotting detection reagent (GE Healthcare Europe).
Chemiluminescent signal was detected using ImageQuant
LAS 4000 analyzer (GE Healthcare). Precision Plus
ProteinTM Dual Color Standards (Bio-Rad) were used to de-
termine the molecular weight of the proteins. Optical density
of each band was measured using ImageJ (Adobe Photoshop
CS5, San Jose, CA, USA). For each sample the optical density
was calculated relative to the optical density of b-tubulin.
Proliferation assay
Proliferation of cell cultures was determined 24 h after treat-
ment by flow cytometric cell cycle analysis as previously
described (Bongaarts et al., 2018; van Scheppingen et al.,
2018). Briefly, 24 h after treatment cells were suspended in
PBS/1% BSA and stained with Fixable Viability Dye eFluor
780 (eBioscience) on ice for 30 min. After fixation in 90%
ethanol, cells were washed twice with PBS, resuspended in
PBS containing 1 mg/ml propidium iodide and 1 g/ml RNase
A and incubated for 10 min at 37C. Cell cycle analysis was
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performed using a FACSCanto Flow Cytometer equipped with
FACSDiva software (BD Biosciences) and data analysis was
performed using FlowJo 7.6 (FlowJo LLC, Ashland, OR,
USA). Viable cells showing a DNA content between G1 and
G2 (S-phase) were selected as proliferative population.
Statistical analysis
Statistical analysis was performed with GraphPad Prism soft-
ware (Graphpad software Inc., La Jolla, CA) using the non-
parametric Mann-Whitney U-test or, for multiple groups, the
non-parametric Kruskal-Wallis test followed by Mann-
Whitney U-test. Correlations were assessed with R using the
Spearman’s rank correlation test. An adjusted P-value 5 0.05
was considered statistically significant.
Data availability
The data that support the findings of this study are openly
available on the European Genome-phenome Archive (EGA),
which is hosted by the EBI and the CRG, under the accession
number: EGAS00001003787.
Results
The protein-coding transcriptome of
SEGAs
To characterize the transcriptome profile of SEGAs RNA-
Seq was performed on total RNA extracted from SEGA
samples and control brain samples. The analysis included
19 SEGA samples from 17 TSC patients and two patients
with no other signs of TSC (all surgical specimens) and
eight area-matched periventricular controls (autopsy speci-
mens) without a history of seizures or other neurological
disease (see ‘Materials and methods’ section and Table 1).
After quality assessment and filtering, 37 million paired-
end reads remained per sample, of which 88% mapped to
the GRCh38 reference genome. A principal component
analysis (PCA) revealed that the major source of variability
in gene expression was the diagnosis (SEGA or control;
Fig. 1A) , which was confirmed by a Spearman’s correl-
ation matrix of the gene expression showing that the con-
trol samples and SEGA samples clustered separately
(Fig. 1B). No specific clustering was seen based on the
TSC mutation (Fig. 1B). To assess other potential confoun-
ders on the transcriptome profile of the samples a principal
variance component analysis (PVCA) was performed.
When all control and SEGA samples were assessed, as ex-
pected, the major contributor to the variance between the
samples was the diagnosis (Supplementary Fig. 1A).
Assessment of clinical features such as, mutation, age,
gender, brain area, drug-treatment, mTORC1 inhibitors,
epilepsy, presence of other TSC lesions or country of
origin demonstrated that no single variable or two-way
interaction was a single major contributor to the variance
seen in the transcriptome profiles of the SEGAs
(Supplementary Fig. 1B).
Differential gene expression analysis revealed 9400 DEGs
(adjusted P 5 0.05) in SEGA compared to control tissue,
of which 4621 genes were overexpressed and 4779 under-
expressed (Fig. 1C and Supplementary Table 3). Among the
9400 DEGs we identified 7196 protein-coding genes, 360
long non-coding RNAs, 309 pseudogenes, 1516 genes of
which the biotype could not be determined by BioMart and
19 genes that could not be linked to a specific category
(Supplementary Table 3). To compare the TSC1 mutated
SEGA samples with the TSC2 mutated SEGA samples, two
differential gene expression analyses were carried out:
TSC1 mutated SEGAs compared to control (TSC1-control)
and TSC2 mutated SEGAs compared to control (TSC2-con-
trol). The majority of the DEGs in both groups (TSC1-con-
trol and TSC2-control) were overlapping (5292 genes),
whereas 721 genes were only found differentially expressed
in TSC1-control and 2816 genes in TSC2-control (Fig. 1D).
Furthermore, the fold changes between TSC1-control and
TSC2-control showed a strong positive correlation
(Spearman’s correlation, rho = 0.89, P 5 0.01).
To understand the organization of the protein-coding
transcriptome of SEGAs better, a gene set enrichment ana-
lysis (GSEA; see ‘Materials and methods’ section) was per-
formed, identifying 145 pathways enriched in SEGA
compared to control tissue (adjusted P 5 0.05). A
Fisher’s exact test revealed 92 pathways (adjusted P 5
0.02) enriched for DEGs (adjusted P 5 0.05; Fig. 1E and
Supplementary Table 5). The SEGA transcriptome profile
was associated with pathways including immune system,
extracellular matrix organization, metabolism and the
MAPK family signalling cascades. These pathways were
also found among the top 25 pathways containing the
highest amount of DEGs (Fig. 1F). Furthermore, most of
the enriched pathways contained more overexpressed genes
then under-expressed genes (Fig. 1F and Supplementary
Table 5).
Previously, Martin et al. (2017) performed RNA-Seq on
13 SEGA samples, two subependymal nodules and eight
normal brain tissue samples. To assess the robustness of
our analysis, we overlapped our DEGs set with that of
Martin et al. (2017) and performed a pathway analysis
(Supplementary Fig. 2A and B). We identified 619 overex-
pressed genes and 777 under-expressed genes in common
between both studies, resulting in 32 enriched pathways
(Supplementary Fig. 2C). As the MAPK pathway was iden-
tified in all pathway analyses performed we decided to
focus on this pathway for further analysis.
Higher expression of LAMTOR genes
in SEGA compared to control tissue
Previous studies have shown that the Ragulator complex
(formed by LAMTOR1, LAMTOR2, LAMTOR3,
LAMTOR4 and LAMTOR5) localizes to the late
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Figure 1 The protein-coding transcriptome of SEGAs. (A) A principal component analysis (PCA) of the RNA-Seq data in SEGA (n = 19)
and periventricular control tissue (n = 8) showing that the major source of variability in gene expression is the diagnosis. x-axis: the first principal
component (PC); y-axis: the second PC. (B) Spearman’s rank correlation matrix of the RNA-Seq data showing separate clustering of SEGAs from
control tissue. The scale bar indicates the strength of the correlation with 1 indicating a strong positive correlation (dark blue) and 0 indicating no
correlation (dark red) between samples. (C) Volcano plot showing the DEGs (adjusted P 5 0.05) between SEGAs and control tissue. A total of
4621 mRNAs were found to be overexpressed and 4779 under-expressed in SEGA compared to control tissue. (D) Spearman’s rank correlation
of the fold changes from TSC1 mutated SEGAs compared to the fold changes from TSC2 mutated SEGAs showing a strong correlation (rho =
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endosomes/lysosomes membrane, where it can activate both
the MAPK/ERK pathway and the mTORC1 pathway (Teis
et al., 2002; Bar-Peled et al., 2012; Nada et al., 2014;
Rebsamen et al., 2015; de Araujo et al., 2017) (Fig. 2A).
Based on our RNA-Seq data we found this complex to be
overexpressed in SEGA compared to control
(Supplementary Table 3). RT-qPCR was used to validate
the RNA-Seq data for LAMTOR1, LAMTOR2,
LAMTOR3, LAMTOR4 and LAMTOR5. All five genes
were found to have higher expression in SEGA compared
to control tissue (LAMTOR1: P = 0.001, LAMTOR2: P =
0.0011, LAMTOR3: P = 0.006, LAMTOR4: P = 0.0325
and LAMTOR5: P = 0.0026; Fig. 2B–F). A protein-protein
interaction network for the Ragulator complex was
assembled using the STRINGapp in Cytoscape and demon-
strated that this complex interacts with proteins related to
the MAPK/ERK pathway, including MAPK1 (ERK2),
MAPK3 (ERK1), RAF1 and BRAF, as well as with proteins
related to the mTORC1 pathway, including RAPTOR,
MTOR, TSC1, TSC2 (Fig. 2G). Furthermore, most of
these interacting proteins in the wider network were
found to be differentially expressed in the RNA-Seq data
and/or belonged to at least one of the enriched pathways
(Fig. 2G).
ERK is activated in SEGA tissue and
co-expressed with LAMTOR1
We next determined whether ERK was activated in SEGA
compared to periventricular control tissue by evaluating the
phosphorylation of ERK1/ERK2 (pERK). Western blotting
showed higher ERK phosporylation in SEGA samples (n =
6; including three SEGAs with evidence of loss of hetero-
zygosity) compared to control (n = 4; Mann-Whitney U-
test, P 5 0.01; Fig. 3A and B). Furthermore, no difference
in pERK was seen between TSC1 (n = 3) and TSC2 (n = 3)
mutated SEGAs. Activity of ERK was also seen in tubers (n
= 4) and angiomyolipoma (n = 1), but not in control
cortex (n = 1) or control kidney tissue (n = 1; Fig. 3C).
LAMTOR1 was present in SEGA samples but not detected
in control tissue (Mann-Whitney U-test, P 5 0.01; Fig. 3A
and B). Although variable, weak expression of LAMTOR1
was seen in cortex control, two tubers and kidney control
but not in the angiomyolipoma (Fig. 3C). The cellular dis-
tribution of LAMTOR1-LAMTOR5 was assessed in SEGA
(n = 6) and periventricular tissue (n = 5) using immuno-
histochemistry (Fig. 3D and E). In control tissue a low to
weak expression of LAMTOR1-LAMTOR5 was seen
mainly in the ependymal lining of lateral ventricles (red
arrows). Furthermore, expression of LAMTOR1-
LAMTOR5 was seen in neurons of cortex tissue
(Supplementary Fig. 4, arrowheads). Both pERK and pS6
were not detected in control tissue (Fig. 3D, E and
Supplementary Fig. 4). In SEGA high expression of
LAMTOR1-LAMTOR5 was seen in giant cells (Fig. 3D,
E, arrows and insets). Furthermore, LAMTOR1-
LAMTOR5 were co-expressed in cells with pERK (mainly
nuclear) and pS6 (mainly cytoplasmic).
Inhibition of ERK with U0126
decreases the proliferation of
primary SEGA cells
We further evaluated the role of ERK in the cell cycle pro-
gression of SEGA cells using flow cytometric cell cycle ana-
lysis in one SEGA-derived cell culture (TSC1 mutated). The
viability of cells was not altered after treatment with the
ERK inhibitor U0126, rapamycin or the combination of
U0126 and rapamycin (Fig. 4A). The percentage of cells
in the S-phase was decreased after treatment with U0126
(P 5 0.01) or rapamycin (P 5 0.01) compared to control
(DMSO; Fig. 4A and B). Combining U0126 with rapamy-
cin also decreased the proliferation of SEGA cells (P 5
0.01) compared to control but not compared to U0126
or rapamycin alone. Inhibition of ERK activity by U0126
was confirmed by western blotting as well as the inhibition
of mTORC1 pathway by rapamycin using pS6 as a readout
(Supplementary Fig. 3).
The small non-coding RNA landscape
of SEGAs
Small RNA-Seq was performed to detect miRNAs and
other small non-coding RNAs in the same cohort of
SEGA and control samples that were used for RNA-Seq.
After quality assessment and filtering, 6 million reads re-
mained, of which 83% were successfully mapped to the
human reference genome GRCh38. Differential expression
testing between SEGA samples and control, identified 140
differentially expressed small RNAs of which 72 were
under-expressed and 68 overexpressed (Fig. 5A and
Supplementary Table 4). Among the differentially expressed
small RNAs we identified one snRNA, three snoRNAs,
four vtRNAs, 94 miRNAs, 15 unannotated gene derived
Figure 1 Continued
0.89, P 5 0.001). The Venn diagram shows 5292 DEGs in common between TSC1 and TSC2 mutated SEGAs, 721 DEGs were specific for TSC1
mutated SEGAs and 2816 DEGs were specific for TSC2 mutated SEGAs. (E) Schematic overview using Cytoscape of pathways enriched in SEGA
compared to control tissue. Geometric testing was used to determine if the amount of DEGs was significant (adjusted P 5 0.02) per pathway.
Lines indicate genes in common between pathways. (F) Graphical representation of overexpressed genes (red) and under-expressed genes (blue)
in 25 enriched pathways containing the highest amount of DEGs.
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Figure 2 The Ragulator complex in SEGAs. (A) Schematic overview showing the Ragulator complex dependent mTORC1/MAPK
signalling. Crystal structure of the Ragulator complex revealed that LAMTOR1 holds together the LAMTOR2/3 and LAMTOR4/5 heterodimers
and anchors the complex to the late endosomes/lysosomes (de Araujo et al., 2017). In the presence of amino acids and growth factors, the
Ragulator complex can promote Rag GTPase- dependent mTORC1 activation and MEK1 dependent ERK activation via direct interaction of RagA-
D and MEK1 with LAMTOR2/3 heterodimer (Teis et al., 2002; Bar-Peled et al., 2012). Furthermore, the Ragulator complex interacts with vacuolar
H + -ATPase and neutral amino acid transporter SLC38A9 and thereby can promote mTORC1 activation in the presence of amino acids
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small RNAs and 23 intergenic small RNAs (Fig. 5B). The
majority of the differentially expressed small RNAs were
miRNAs (67.2%) of which 49 were under-expressed in
SEGA compared to control and 45 were miRNAs were
overexpressed (Fig. 5B and C). The unannotated gene
derived and intergenic small RNAs, as defined in the ma-
terials and methods, formed the second and third largest
groups of differentially expressed small RNAs, respectively.
Overall 16.4% of the differentially expressed small RNAs
were intergenic and 10.7% were gene derived.
Next we analysed which miRNAs could interact with the
92 enriched pathways from GSEA by assessing each path-
way using a Fisher’s exact test, for an over-representation
of validated miRNA targets of each differentially expressed
miRNA. A total of 81 pathways were found to be enriched
for validated targets of 45 of the differentially expressed
miRNAs (Fisher’s exact test, adjusted P 5 0.05;
Fig. 5D). miRNA-20a-5p, miRNA-34a-5p, miRNA-130b-
3p and miRNA-181a-5p were selected for validation
using RT-qPCR and were found differentially expressed
in accordance with the RNA-Seq data (Fig. 5E).
To identify miRNAs that could target one or more of
LAMTOR1, LAMTOR2, LAMTOR3, LAMTOR4 or
LAMTOR5, differentially expressed miRNAs were evalu-
ated with miRWalk2. LAMTOR1 was found to be a vali-
dated target of miRNA-20a-5p and let-7c-5p, LAMTOR3
was found to be a validated target of miRNA-362-3p and
miRNA-548ba and LAMTOR5 was found to be a vali-
dated target of miRNA-221-3p and miRNA-501-5p.
Spearman correlations using the RNA-Seq data were calcu-
lated between each miRNA and their validated identified
target. This analysis identified miRNA-20a-5p (adjusted P
= 0.012, rho = –0.55) and miRNA-221-3p (adjusted P =
0.015, rho = 0.51) as potentially interesting regulatory
partners of LAMTOR1 and LAMTOR5 respectfully.
Based on these results miRNA-20a-5p was selected for fur-
ther analysis. Transfection of primary foetal astrocytes with
miRNA-20a-5p mimic showed that miRNA-20a-5p could
downregulate LAMTOR1 (P = 0.0022), LAMTOR2 (P =
0.0087) and LAMTOR5 (P = 0.026), but not LAMTOR3
(P = 0.4848) or LAMTOR4 (P = 0.0649; Fig. 6).
Discussion
In this study we performed parallel sequencing of the
coding and non-coding transcriptome of SEGAs from
TSC patients. Among the differentially expressed protein-
coding genes we identified an enrichment for genes related
to the MAPK pathway. ERK activation in SEGA was con-
firmed on protein level and was also found in tubers. Both
the ERK inhibitor U0126 and rapamycin were able to de-
crease the proliferation of SEGA cells of one SEGA-derived
cell culture in vitro. Additionally, we showed that genes
related to the Ragulator complex, a complex activating
both the MAPK/ERK and mTORC1 pathway, were over-
expressed in SEGA compared to control tissue. Therefore,
we provide initial evidence of linkage between these two
important pathways of tumour growth and cell survival.
In the present study, high-throughput sequencing of both
coding and non-coding transcriptome was performed on 19
SEGAs and eight periventricular control tissue. We identi-
fied substantial gene expression changes in SEGAs com-
pared to periventricular control tissue. These gene
expression changes appear to be independent of the
TSC1/TSC2 mutation or other clinical information avail-
able. Pathway enrichment analysis identified 116 pathways
enriched in SEGA compared to control tissue, including
immune system, extracellular matrix organization, metab-
olism, transmission across chemical synapses and the
MAPK family signalling cascades. Several of the enriched
pathways found in our study are related to the biological
processes found in previous transcriptome-based SEGA stu-
dies (Tyburczy et al., 2010; Martin et al., 2017).
Differential expression of genes related to the immune
system has also been identified in cortical tubers through
the use of RNA-Seq and microarrays (Boer et al., 2010;
Martin et al., 2017; Mills et al., 2017). Multiple studies
of TSC animal models and TSC human tissue, including
prenatal TSC lesions have documented dysregulation of in-
flammation related pathways, such as immune response,
suggesting that this biological process is more conserved
across TSC pathology rather than a SEGA specific process
(Boer et al., 2008, 2010; Zurolo et al., 2011; Prabowo
et al., 2013; Zhang et al., 2015). One of the enriched path-
ways found in this study was the MAPK pathway. Previous
studies focusing on TSC2 mutated tubers and SEGAs in
which the TSC2 protein is still present documented the
presence of MAPK/ERK activation (Han et al., 2004; Ma
et al., 2005, 2007). In accordance with these studies we
show that ERK activation is present in tubers and SEGA
and that the activation of ERK seen in SEGAs seems to be
independent of TSC1/TSC2 mutation and loss of
Figure 2 Continued
(Rebsamen et al., 2015; Wang et al., 2015). Rapamycin inhibits mTORC1, whereas U0126 inhibits the MEK1 dependent ERK activation. (B–F) RT-
qPCR of LAMTOR1 (B), LAMTOR2 (C), LAMTOR3 (D), LAMTOR4 (E) and LAMTOR5 (F) in SEGA (n = 19) compared to control tissue (n = 8), which
together can form the Ragulator complex. Data are expressed relative to the expression observed in control tissue. P 5 0.05, P 5 0.01, P
5 0.001, Mann-Whitney U-test. (G) A String functional protein association network of the Ragulator complex (LAMTOR1–LAMTOR5) inter-
actions identified by StringApp for Cytoscape. High confidence interactions were selected (0.7), identifying interactions with proteins related to
the MAPK/ERK and mTORC1 pathway. The outer circle indicates overexpression (red) or under-expression (blue) on RNA level based on the
RNA-Seq data. The inner circle indicates to which enriched pathways each protein-interactor belongs to.
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Figure 3 ERK activation and LAMTOR1-LAMTOR5 protein expression in SEGAs. (A) Western blot showing pERK1/2 and
LAMTOR1 expression in SEGA [n = 6; TSC1 mutated: sample 1–3 and TSC2 mutated: samples 4–6; loss of heterozygosity: samples 3, 4 and 6; loss
of heterozygosity identified as described in Bongaarts et al. (2017)] but not in periventricular control tissue (n = 4). b-tubulin was used as a loading
control. (B) Quantification of pERK1/2 and LAMTOR1 signals normalized to either total ERK1/2 or b-tubulin. P 5 0.01, Mann-Whitney U-test.
(C) Western blot showing pERK1/2 and LAMTOR1 expression in SEGA (n = 4), cortical tubers (n = 4) and angiomyolipoma (AML; n = 1) but not
in periventricular control tissue (n = 1: sample C1), cortex control (n = 1; sample C2) and normal kidney tissue (n = 1; sample C3). b-tubulin was
used as a loading control. (D and E) Immunohistochemistry for pERK1/2 (red, D) or pS6 (red, E) together with LAMTOR1–LAMTOR5 (blue) on
SEGA (n = 6) and periventricular control tissue (n = 5). Insets show a higher magnification of giant cells (indicated with arrows) in SEGA and red
arrows indicate the ependymal lining of lateral ventricles. Scale bar = 200 mm; insets = 100 mm.
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Figure 4 ERK inhibitor U0126 and rapamycin inhibit proliferation of SEGA cells in vitro. (A) Primary SEGA cells from one SEGA-
derived cell culture were stimulated for 24 h with U0126 (5 mM), rapamycin (0.01 mM), a combination of rapamycin with U0126 (rapamycin +
U0126) or DMSO (0.05%) as a control. Flow cytometry analysis was used to assay the viability with eFluor or the cell-cycle state using propidium
iodide (PI) staining of SEGA cells (n = 5). (B) Quantification of the PI staining showed lesser cells in the S-phase in the U0126, rapamycin and the
rapamycin + U0126 conditions compared to control (0.05% DMSO). Data are expressed relative to the control condition. P 5 0.01, Kruskal-
Wallis test followed by Mann-Whitney U-test.
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Figure 5 The small non-coding RNA landscape of SEGAs. (A) Volcano plot showing 72 under-expressed and 68 overexpressed small
RNAs in SEGA (n = 19) compared to control tissue (n = 8; adjusted P 5 0.05). (B) Pie chart showing the distribution of different small RNAs
differentially expressed in SEGA compared to control. miRNA = microRNA; snRNA = small nuclear RNA; snoRNA = small nucleolar RNA;
vtRNA = vault RNA. (C) Volcano plot showing 49 under-expressed and 45 overexpressed miRNAs in SEGA (n = 19) compared to control tissue
(n = 8; adjusted P 5 0.05). (D) Heat map showing 81/92 enriched pathways from GSEA that were enriched for validated targets of 45/94 of the
differentially expressed miRNAs (Fisher’s exact test, adjusted P 5 0.05). Pathways enriched for a specific miRNA are indicted with a green box.
(E) Validation of selected differentially expressed miRNAs (miRNA-20a-5p, miRNA-34a-5p, miRNA-130b-3p and miRNA-181a-5p) in SEGA (n =
19) compared to control tissue (n = 8) using TaqManTM PCR. P 5 0.01, P 5 0.001, Mann-Whitney U-test.








roningen user on 24 April 2020
heterozygosity. Therefore, it could be of interest to investi-
gate the MAPK/ERK activation further in other TSC-
related lesions.
Current treatment of SEGAs is limited to surgical re-
moval and mTORC1 inhibitors, including rapamycin and
everolimus (Franz et al., 2006, 2013, 2014, 2015; Krueger
et al., 2010, 2013; Kotulska et al., 2013). In recent TSC
clinical trials, it was shown that responses to mTORC1
inhibitors can be variable and that lesions tend to relapse
after cessation of treatment (Franz et al., 2006, 2014;
Bissler et al., 2008; Krueger et al., 2010, 2016;
McCormack et al., 2011; Martins et al., 2013). A possible
explanation for this could be that inhibition of mTORC1
leads to the disruption of the negative feedback on the
MAPK/ERK pathway resulting in MAPK/ERK activation
(Carracedo et al., 2008; Albert et al., 2009). Furthermore,
MAPK/ERK activation can result in TSC2 phosphorylation
and thereby increase mTORC1 activation, indicating that
these two pathways are intrinsically linked (Han et al.,
2004; Ma et al., 2005, 2007). Only two patients included
in the present study were treated with mTORC1 inhibitors,
indicating that the ERK activation seen cannot be explained
by mTORC1 inhibition. Previous studies have shown that
inhibiting MAPK/ERK activity decreased the proliferation
of Tsc2–/– mouse embryonic fibroblast cells, SEGA cells and
tumour growth in mice heterozygous for Tsc2
(Govindarajan et al., 2003; Mi et al., 2009; Tyburczy
et al., 2010). In accordance with these studies, we show
that inhibiting ERK in a primary human derived SEGA
culture using the ERK inhibitor U0126 decreased the pro-
liferation in a similar manner to treatment with rapamycin
as a mTORC1 inhibitor alone. In contrast to previous re-
search, we did not observe differences between rapamycin
and combined therapy with rapamycin and the ERK inhibi-
tor U0126 in SEGA cells from one SEGA-derived cell cul-
ture (Mi et al., 2009; Tyburczy et al., 2010). A previous
study by Mi et al. (2009) identified that combined treat-
ment of rapamycin and ERK inhibitors was more efficient
in inhibiting the proliferation of TSC2 deficient cells then
treatment with rapamycin or ERK inhibitors alone after
3 days of treatment, but not over shorter time periods.
Furthermore, Tyburczy et al. (2010) showed that suppres-
sion of both the mTORC1 and MAPK/ERK pathway was
most efficient in decreasing proliferation after 48 h and cell
viability after 3 days of treatment compared to mTORC1
or ERK inhibition alone (Tyburczy et al., 2010). This sug-
gests that combined therapy may be only beneficial over a
longer period of time. However, considering the side ef-
fects, it may also be difficult to treat patients with multiple
inhibitors at the same time (Sadowski et al., 2016; Cheng
and Tian, 2017). Therefore, therapeutic interventions re-
sulting in decreased MAPK signalling in SEGA could be
used as an alternative to the current treatments available,
especially in TSC patients who do not adequately respond
to mTORC1 inhibitors. However, the need for more spe-
cific treatment remains. As the MAPK/ERK pathway is
known to regulate cell proliferation but has also been
linked to epilepsy, patients with other TSC lesions, such
as tubers, may also benefit from treatment with MAPK/
ERK inhibitors; however, further investigation is highly
needed (Nateri et al., 2007; de Araujo Herculano et al.,
2011; Gorter et al., 2014; Glazova et al., 2015; Pernice
et al., 2016; Shao et al., 2016).
To the best of our knowledge the mechanism that acti-
vates the MAPK/ERK pathway in SEGA and other TSC
lesions has not been determined. Previous studies have
demonstrated that the Ragulator complex (LAMTOR1–
LAMTOR5) is involved in lysosomal positioning, autop-
hagy and the activation of both MAPK/ERK and
mTORC1 pathways in the presence of nutrients and
growth factors (Teis et al., 2002; Bar-Peled et al., 2012;
de Araujo et al., 2017; Filipek et al., 2017). It has been
shown that the Ragulator complex is necessary for the lo-
calization and stabilization of RAG GTPases (RagA-RagD)
and mTORC1 to the late endosomes/lysosomes membrane,
which is required for amino acid-dependent activation of
mTORC1 (Sancak et al., 2010; Bar-Peled et al., 2012).
Furthermore, the Ragulator complex can also activate the
Figure 6 Relative expression of LAMTOR genes after transfection with miRNA-20a-5p mimic in foetal astrocytes. TaqManTM
PCR of miRNA-20a-5p (A) and RT-qPCR of LAMTOR1 (B), LAMTOR2 (C), LAMTOR3 (D), LAMTOR4 (E) and LAMTOR5 (F) in foetal astrocytes
transfected with miRNA-20a-5p mimic (miR20a) for 24h (n = 3 biological triplets and two technical duplicates). Data are normalized to
Lipofectamine (control). P 5 0.05, P 5 0.01, Mann-Whitney U-test.
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MAPK/ERK pathway by recruiting MEK1 to the late endo-
somes/lysosomes (Wunderlich et al., 2001; Teis et al.,
2002). Although the involvement of the Ragulator complex
in the mTORC1 and MAPK/ERK signalling is well estab-
lished, the role of this complex in human pathology has
rarely been studied. In the present study, we identified the
Ragulator complex (LAMTOR1–LAMTOR5) to be over-
expressed in SEGAs compared to control tissue. RNA-Seq
on tubers did not find an overexpression of LAMTOR
genes in tubers, suggesting that overexpression of this com-
plex is unique to SEGA (Martin et al., 2017; Mills et al.,
2017). While we found weak expression of LAMTOR1 in
a subset of tubers, expression of LAMTOR1 was also seen
in neurons of healthy control tissue, which could explain
why no difference was found on RNA level between tubers
and cortex control in previous studies (Martin et al., 2017;
Mills et al., 2017). Furthermore, we show that
LAMTOR1–5 co-express with pERK and pS6 suggesting
that the Ragulator complex might be involved with the
activation of these two pathways in SEGA and could be
an interesting target for therapy. However, further research
is needed to show the direct link between the Ragulator
complex and SEGA development.
So far, research on small non-coding RNAs in SEGA has
been limited to miRNA expression using microarray analysis
or direct RT-qPCR (Ames et al., 2017; Bongaarts et al.,
2018). In this study we mapped the whole small non-
coding RNA profile in SEGAs relative to control tissue
and found that miRNAs, snRNAs, snoRNAs and vtRNAs
were amongst the differentially expressed small RNAs. We
identified miRNAs as the largest group of differentially ex-
pressed small RNAs. As miRNAs are known regulators of
gene expression we used a bioinformatics approach to iden-
tify miRNAs that could potentially modulate the enriched
pathways found in this study. In doing so, we identified
miRNA-20a-5p as a potential regulator of several
LAMTOR genes. We also identified a high number of unan-
notated small transcripts. Although these unannotated small
RNAs still need to be validated and functionally character-
ized, they could potentially harbour novel small RNAs and
therefore be interesting for further research.
Taken together, this study shows activation of ERK in
SEGAs and suggests that the MAPK/ERK pathway could
be used as a target for treatment independent of, or in
combination with mTORC1 inhibitors for TSC patients
with SEGAs. Furthermore, we are the first to identify the
overexpression of the Ragulator complex in human path-
ology, linking the constitutive activated mTORC1 pathway
and MAPK/ERK activation seen in SEGAs, highlighting the
Ragulator complex as a promising novel therapeutic target.
Acknowledgements
The authors thank all supporters of the TSC brain bank
(Laboratory of Molecular and Cellular Neurobiology,
International Institute of Molecular and Cell Biology,
Warsaw, Poland: J. Jaworski, A Tempes; The Service
d’Anatomie Pathologique, CHI de Creteil and Inserm
U676, Hospital Robert Debre, Paris, France: H. Adle-
Biassette; Department of Pediatrics, Institute of
Neurology, Department of Neurosurgery, Medical
University Vienna, Austria: M. Feucht, T. Scholl, J.
Hainfellner, T. Czech; Department of Neurology and
Pathology and Molecular Medicine, Charles University,
2nd Faculty of Medicine, Motol University Hospital,
Prague, Czech Republic: P. Krsek, J. Zamecnik;
Department of Neuropathology, John Radcliffe Hospital,
Oxford, UK: C. Kennard; Department of Anatomic
Pathology Sciences, Università Sapienza, Rome, Italy: M.
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Turkey: F. Söylemezoğlu). In this regard we would like to
acknowledge all personnel involved in sending us the ma-
terial. Furthermore, the authors would like to thank Dr
Mark Nellist (Department of Clinical Genetics, Erasmus
Medical Centre, Rotterdam, The Netherlands) and Dr
David J. Kwiatkowski, MD, PhD (Division of
Experimental Medicine and Medical Oncology, Brigham
and Women’s Hospital, Boston, USA) for performing
TSC1/TSC2 mutation analysis.
Funding
This work was supported by KIKA (Stichting Kinderen
Kankervrij; A.B., A.M., B.S., E.A.); Stichting AMC
Foundation (E.A.); Stichting TSC Fonds (E.A.); the
Austrian Science Fund (FWF, no. J3499; A.M.); the
European Union 7th framework program: acronym
EPISTOP (grant agreement no. 602391; J.S., F.J., T.S., S.J.,
M.F., A.M., E.A.); the European Union 7th framework pro-
gram: acronym DESIRE (grant agreement no. 602531; I.B.);
the Polish Ministerial funds for science (Years 2013–2018)
for the implementation of international co-financed project
(K.K., S.J.) and internal research project of the Children’s
Memorial Health Institute no.S132/2013 (K.K., S.J.).
Competing interests
The authors report no competing interests. We confirm that
we have read the Journal’s position on issues involved in








roningen user on 24 April 2020
ethical publication and affirm that this report is consistent
with those guidelines.
Supplementary material
Supplementary material is available at Brain online.
References
Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA,
Zonnenberg BA, Prokop M. Prevalence of subependymal giant cell
tumors in patients with tuberous sclerosis and a review of the lit-
erature. Eur J Neurol 2009; 16: 691–6.
Albert L, Karsy M, Murali R, Jhanwar-Uniyal M. Inhibition of mTOR
activates the MAPK pathway in Glioblastoma multiforme. Cancer
Genomics Proteomics 2009; 6: 255–61.
Ames HM, Yuan M, Vizcaino MA, Yu W, Rodriguez FJ. MicroRNA
profiling of low-grade glial and glioneuronal tumors shows an inde-
pendent role for cluster 14q32.31 member miR-487b. Mod Pathol
2017; 30: 204–16.
Aronica E, Becker AJ, Spreafico R. Malformations of cortical develop-
ment. Brain Pathol 2012; 22: 380–401.
Aronica E, Crino PB. Epilepsy related to developmental tumors and
malformations of cortical development. Neurotherapeutics 2014; 11:
251–68.
Bar-Peled L, Schweitzer LD, Zoncu R, Sabatini DM. Ragulator is a
GEF for the rag GTPases that signal amino acid levels to mTORC1.
Cell 2012; 150: 1196–208.
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard
JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis com-
plex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140–
51.
Boer K, Crino PB, Gorter JA, Nellist M, Jansen FE, Spliet WG, et al.
Gene expression analysis of tuberous sclerosis complex cortical
tubers reveals increased expression of adhesion and inflammatory
factors. Brain Pathol 2010; 20: 704–19.
Boer K, Jansen F, Nellist M, Redeker S, van den Ouweland AM, Spliet
WG, et al. Inflammatory processes in cortical tubers and subepen-
dymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res
2008; 78: 7–21.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for
Illumina sequence data. Bioinformatics 2014; 30: 2114–20.
Bongaarts A, Giannikou K, Reinten RJ, Anink JJ, Mills JD, Jansen FE,
et al. Subependymal giant cell astrocytomas in Tuberous sclerosis
complex have consistent TSC1/TSC2 biallelic inactivation, and no
BRAF mutations. Oncotarget 2017; 8: 95516–29.
Bongaarts A, Prabowo AS, Arena A, Anink JJ, Reinten RJ, Jansen FE,
et al. MicroRNA519d and microRNA4758 can identify ganglioglio-
mas from dysembryoplastic neuroepithelial tumours and astrocyto-
mas. Oncotarget 2018; 9: 28103–15.
Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti
A, et al. Inhibition of mTORC1 leads to MAPK pathway activation
through a PI3K-dependent feedback loop in human cancer. J Clin
Invest 2008; 118: 3065–74.
Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-
Kowalik J, et al. Pathogenesis of tuberous sclerosis subependymal
giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2
leads to mTOR activation. J Neuropathol Exp Neurol 2004; 63:
1236–42.
Cheng Y, Tian H. Current development status of MEK inhibitors.
Molecules 2017; 22: 1551.
Croft D, O’Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al.
Reactome: a database of reactions, pathways and biological pro-
cesses. Nucleic Acids Res 2011; 39: D691–7.
Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL.
Subependymal giant cell astrocytoma in children with tuberous
sclerosis. Childs Nerv Syst 2003; 19: 232–43.
de Araujo Herculano B, Vandresen-Filho S, Martins WC, Boeck CR,
Tasca CI. NMDA preconditioning protects against quinolinic acid--
induced seizures via PKA, PI3K and MAPK/ERK signaling path-
ways. Behav Brain Res 2011; 219: 92–7.
de Araujo MEG, Naschberger A, Furnrohr BG, Stasyk T,
Dunzendorfer-Matt T, Lechner S, et al. Crystal structure of the
human lysosomal mTORC1 scaffold complex and its impact on
signaling. Science 2017; 358: 377–81.
de Ribaupierre S, Dorfmuller G, Bulteau C, Fohlen M, Pinard JM,
Chiron C, et al. Subependymal giant-cell astrocytomas in pediatric
tuberous sclerosis disease: when should we operate? Neurosurgery
2007; 60: 83–9; discussion 9–90.
Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, et al.
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream
of mTORC1. Mol Cell 2012; 47: 535–46.
DiMario FJ Jr. Brain abnormalities in tuberous sclerosis complex.
J Child Neurol 2004; 19: 650–7.
Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape
StringApp: network analysis and visualization of proteomics data.
J Proteome Res 2019; 18: 623–32.
Dweep H, Gretz N, Sticht C. miRWalk database for miRNA-target
interactions. Methods Mol Biol 2014; 1182: 289–305.
Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction
of possible miRNA binding sites by “walking” the genes of three
genomes. J Biomed Inform 2011; 44: 839–47.
European Chromosome 16 Tuberous Sclerosis Consortium.
Identification and characterization of the tuberous sclerosis gene
on chromosome 16. Cell 1993; 75: 1305–15.
Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M,
Garapati P, et al. The reactome pathway knowledgebase. Nucleic
Acids Res 2018; 46: D649–55.
Filipek PA, de Araujo MEG, Vogel GF, De Smet CH, Eberharter D,
Rebsamen M, et al. LAMTOR/Ragulator is a negative regulator of
Arl8b- and BORC-dependent late endosomal positioning. J Cell Biol
2017; 216: 4199–215.
Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley
K, et al. Everolimus for subependymal giant cell astrocytoma: 5-year
final analysis. Ann Neurol 2015; 78: 929–38.
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman
R, et al. Everolimus for subependymal giant cell astrocytoma in
patients with tuberous sclerosis complex: 2-year open-label exten-
sion of the randomised EXIST-1 study. Lancet Oncol 2014; 15:
1513–20.
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman
R, et al. Efficacy and safety of everolimus for subependymal giant
cell astrocytomas associated with tuberous sclerosis complex
(EXIST-1): a multicentre, randomised, placebo-controlled phase 3
trial. Lancet 2013; 381: 125–32.
Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G,
et al. Rapamycin causes regression of astrocytomas in tuberous
sclerosis complex. Ann Neurol 2006; 59: 490–8.
Fujiwara S, Takaki T, Hikita T, Nishio S. Subependymal giant-cell
astrocytoma associated with tuberous sclerosis. Do subependymal
nodules grow? Childs Nerv Syst 1989; 5: 43–4.
Glazova MV, Nikitina LS, Hudik KA, Kirillova OD, Dorofeeva NA,
Korotkov AA, et al. Inhibition of ERK1/2 signaling prevents epilep-
tiform behavior in rats prone to audiogenic seizures. J Neurochem
2015; 132: 218–29.
Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tu-
berous sclerosis complex. Neurology 2004; 63: 1457–61.
Gorter JA, Iyer A, White I, Colzi A, van Vliet EA, Sisodiya S, et al.
Hippocampal subregion-specific microRNA expression during epi-
leptogenesis in experimental temporal lobe epilepsy. Neurobiol Dis
2014; 62: 508–20.








roningen user on 24 April 2020
Govindarajan B, Mizesko MC, Miller MS, Onda H, Nunnelley M,
Casper K, et al. Tuberous sclerosis-associated neoplasms express
activated p42/44 mitogen-activated protein (MAP) kinase, and in-
hibition of MAP kinase signaling results in decreased in vivo tumor
growth. Clin Cancer Res 2003; 9: 3469–75.
Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools
for microRNA genomics. Nucleic Acids Res 2008; 36: D154–8.
Han S, Santos TM, Puga A, Roy J, Thiele EA, McCollin M, et al.
Phosphorylation of tuberin as a novel mechanism for somatic inacti-
vation of the tuberous sclerosis complex proteins in brain lesions.
Cancer Res 2004; 64: 812–6.
Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M,
Kokocinski F, et al. GENCODE: the reference human genome an-
notation for The ENCODE Project. Genome Res 2012; 22: 1760–
74.
Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment
tools: paths toward the comprehensive functional analysis of large
gene lists. Nucleic Acids Res 2009a; 37: 1–13.
Huang da W, Sherman BT, Lempicki RA. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources.
Nat Protoc 2009b; 4: 44–57.
Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of
TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;
17: 1829–34.
Jozwiak S, Mandera M, Mlynarski W. Natural history and current
treatment options for subependymal giant cell astrocytoma in tuber-
ous sclerosis complex. Semin Pediatr Neurol 2015; 22: 274–81.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL.
TopHat2: accurate alignment of transcriptomes in the presence of
insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.
Kingswood JC, d’Augeres GB, Belousova E, Ferreira JC, Carter T,
Castellana R, et al. TuberOus SClerosis registry to increase disease
awareness (TOSCA)-baseline data on 2093 patients. Orphanet J
Rare Dis 2017; 12: 2.
Korotkov A, Broekaart DWM, van Scheppingen J, Anink JJ, Baayen
JC, Idema S, et al. Increased expression of matrix metalloproteinase
3 can be attenuated by inhibition of microRNA-155 in cultured
human astrocytes. J Neuroinflamm 2018; 15: 211.
Kothare SV, Singh K, Chalifoux JR, Staley BA, Weiner HL, Menzer K,
et al. Severity of manifestations in tuberous sclerosis complex in
relation to genotype. Epilepsia 2014; 55: 1025–9.
Kotulska K, Borkowska J, Roszkowski M, Mandera M, Daszkiewicz
P, Drabik K, et al. Surgical treatment of subependymal giant cell
astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol
2014; 50: 307–12.
Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczynski D,
Kmiec T, et al. Long-term effect of everolimus on epilepsy and
growth in children under 3 years of age treated for subependymal
giant cell astrocytoma associated with tuberous sclerosis complex.
Eur J Paediatr Neurol 2013; 17: 479–85.
Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN.
Everolimus long-term safety and efficacy in subependymal giant cell
astrocytoma. Neurology 2013; 80: 574–80.
Krueger DA, Care MM, Holland K, Agricola K, Tudor C,
Mangeshkar P, et al. Everolimus for subependymal giant-cell astro-
cytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801–11.
Krueger DA, Wilfong AA, Mays M, Talley CM, Agricola K, Tudor C,
et al. Long-term treatment of epilepsy with everolimus in tuberous
sclerosis. Neurology 2016; 87: 2408–15.
Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose
program for assigning sequence reads to genomic features.
Bioinformatics 2014; 30: 923–30.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger
D, Cavenee WK, et al. The 2016 World Health Organization clas-
sification of tumors of the central nervous system: a summary. Acta
Neuropathol 2016; 131: 803–20.
Love MI, Huber W, Anders S. Moderated estimation of fold change
and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;
15: 550.
Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP.
Phosphorylation and functional inactivation of TSC2 by Erk impli-
cations for tuberous sclerosis and cancer pathogenesis. Cell 2005;
121: 179–93.
Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D,
et al. Identification of S664 TSC2 phosphorylation as a marker for
extracellular signal-regulated kinase mediated mTOR activation in
tuberous sclerosis and human cancer. Cancer Res 2007; 67: 7106–12.
Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed
KE, et al. The genomic landscape of tuberous sclerosis complex. Nat
Commun 2017; 8: 15816.
Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S,
et al. A review of oral toxicity associated with mTOR inhibitor
therapy in cancer patients. Oral Oncol 2013; 49: 293–8.
McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K,
et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
N Engl J Med 2011; 364: 1595–606.
Mi R, Ma J, Zhang D, Li L, Zhang H. Efficacy of combined inhibition
of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis
complex cell model. J Genet Genomics 2009; 36: 355–61.
Mills JD, Iyer AM, van Scheppingen J, Bongaarts A, Anink JJ, Janssen
B, et al. Coding and small non-coding transcriptional landscape of
tuberous sclerosis complex cortical tubers: implications for patho-
physiology and treatment. Sci Rep 2017; 7: 8089.
Mizuguchi M, Takashima S. Neuropathology of tuberous sclerosis.
Brain Dev 2001; 23: 508–15.
Morimoto K, Mogami H. Sequential CT study of subependymal giant-
cell astrocytoma associated with tuberous sclerosis. Case report.
J Neurosurg 1986; 65: 874–7.
Nabbout R, Santos M, Rolland Y, Delalande O, Dulac O, Chiron C. Early
diagnosis of subependymal giant cell astrocytoma in children with tuber-
ous sclerosis. J Neurol Neurosurg Psychiatry 1999; 66: 370–5.
Nada S, Mori S, Takahashi Y, Okada M. p18/LAMTOR1: a late
endosome/lysosome-specific anchor protein for the mTORC1/
MAPK signaling pathway. Methods Enzymol 2014; 535: 249–63.
Nateri AS, Raivich G, Gebhardt C, Da Costa C, Naumann H,
Vreugdenhil M, et al. ERK activation causes epilepsy by stimulating
NMDA receptor activity. EMBO J 2007; 26: 4891–901.
Northrup H, Krueger DA, International Tuberous Sclerosis Complex
Consensus G. Tuberous sclerosis complex diagnostic criteria update:
recommendations of the 2012 International Tuberous Sclerosis
Complex Consensus Conference. Pediatr Neurol 2013; 49: 243–54.
Pernice HF, Schieweck R, Kiebler MA, Popper B. mTOR and MAPK:
from localized translation control to epilepsy. BMC Neurosci 2016;
17: 73.
Prabowo AS, Anink JJ, Lammens M, Nellist M, van den Ouweland
AM, Adle-Biassette H, et al. Fetal brain lesions in tuberous sclerosis
complex: TORC1 activation and inflammation. Brain Pathol 2013;
23: 45–59.
Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free
analysis of quantitative real-time polymerase chain reaction (PCR)
data. Neurosci Lett 2003; 339: 62–6.
Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M,
Kandasamy RK, et al. SLC38A9 is a component of the lysosomal
amino acid sensing machinery that controls mTORC1. Nature 2015;
519: 477–81.
Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van
den Hoff MJ, et al. Amplification efficiency: linking baseline and
bias in the analysis of quantitative PCR data. Nucleic Acids Res
2009; 37: e45.
Sadowski K, Kotulska K, Jozwiak S. Management of side effects of
mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep
2016; 68: 536–42.








roningen user on 24 April 2020
Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini
DM. Ragulator-Rag complex targets mTORC1 to the lysosomal
surface and is necessary for its activation by amino acids. Cell
2010; 141: 290–303.
Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-
Peled L, et al. The Rag GTPases bind raptor and mediate amino acid
signaling to mTORC1. Science 2008; 320: 1496–501.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D,
et al. Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res 2003; 13: 2498–
504.
Shao Y, Wang C, Hong Z, Chen Y. Inhibition of p38 mitogen-
activated protein kinase signaling reduces multidrug transporter ac-
tivity and anti-epileptic drug resistance in refractory epileptic rats.
J Neurochem 2016; 136: 1096–105.
Smedley D, Haider S, Ballester B, Holland R, London D, Thorisson G,
et al. BioMart–biological queries made easy. BMC Genomics 2009;
10: 22.
Teis D, Wunderlich W, Huber LA. Localization of the MP1-MAPK
scaffold complex to endosomes is mediated by p14 and required for
signal transduction. Dev Cell 2002; 3: 803–14.
Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al.
Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufflinks. Nat Protoc 2012; 7:
562–78.
Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, Kucharska
J, Grajkowska W, et al. Novel proteins regulated by mTOR in
subependymal giant cell astrocytomas of patients with tuberous
sclerosis complex and new therapeutic implications. Am J Pathol
2010; 176: 1878–90.
van Scheppingen J, Iyer AM, Prabowo AS, Muhlebner A, Anink JJ,
Scholl T, et al. Expression of microRNAs miR21, miR146a, and
miR155 in tuberous sclerosis complex cortical tubers and their regu-
lation in human astrocytes and SEGA-derived cell cultures. Glia
2016; 64: 1066–82.
van Scheppingen J, Mills JD, Zimmer TS, Broekaart DWM, Iori V,
Bongaarts A, et al. miR147b: A novel key regulator of interleukin 1
beta-mediated inflammation in human astrocytes. Glia 2018; 66:
1082–97.
van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B,
Verhoef S, et al. Identification of the tuberous sclerosis gene TSC1
on chromosome 9q34. Science 1997; 277: 805–8.
Varemo L, Nielsen J, Nookaew I. Enriching the gene set analysis of
genome-wide data by incorporating directionality of gene expression
and combining statistical hypotheses and methods. Nucleic Acids
Res 2013; 41: 4378–91.
Wang S, Tsun ZY, Wolfson RL, Shen K, Wyant GA, Plovanich ME,
et al. Metabolism. Lysosomal amino acid transporter SLC38A9 sig-
nals arginine sufficiency to mTORC1. Science 2015; 347: 188–94.
Wunderlich W, Fialka I, Teis D, Alpi A, Pfeifer A, Parton RG, et al. A
novel 14-kilodalton protein interacts with the mitogen-activated pro-
tein kinase scaffold mp1 on a late endosomal/lysosomal compart-
ment. J Cell Biol 2001; 152: 765–76.
Zhang B, Zou J, Rensing NR, Yang M, Wong M. Inflammatory mech-
anisms contribute to the neurological manifestations of tuberous
sclerosis complex. Neurobiol Dis 2015; 80: 70–9.
Zurolo E, Iyer A, Maroso M, Carbonell C, Anink JJ, Ravizza T, et al.
Activation of toll-like receptor, RAGE and HMGB1 signalling in
malformations of cortical development. Brain 2011; 134: 1015–32.








roningen user on 24 April 2020
